免疫检查点抑制剂所致的免疫相关皮肤不良事件。
Immune-related cutaneous adverse events due to checkpoint inhibitors.
作者信息
Wang Evelyn, Kraehenbuehl Lukas, Ketosugbo Kwami, Kern Jeffrey A, Lacouture Mario E, Leung Donald Y M
机构信息
Department of Pediatrics, National Jewish Health, Denver, Colorado.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Swim Across America/Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
Ann Allergy Asthma Immunol. 2021 Jun;126(6):613-622. doi: 10.1016/j.anai.2021.02.009. Epub 2021 Feb 17.
OBJECTIVE
To familiarize the reader with the most common cutaneous adverse events with immune checkpoint inhibitors (CPIs) and their grading and treatment.
DATA SOURCES
Recent research articles, relevant review articles, and case series/reports in English from the PubMed database mostly, from 2010 onward.
STUDY SELECTIONS
Most data are from retrospective studies and case series. Older studies regarding the mechanism were included if they were of particular importance.
RESULTS
An understanding of this review should enable the reader to identify specific skin disorders in patients receiving immune CPIs, grade the adverse event, and be able to treat or refer the patient as needed.
CONCLUSION
Allergists/immunologists need to be familiar with these immune-related cutaneous adverse events because their incidence will increase with the ever-expanding use of CPIs and, in particular, because patients will certainly continue to be referred suspecting drug allergies.
目的
使读者熟悉免疫检查点抑制剂（CPI）最常见的皮肤不良事件及其分级和治疗。
数据来源
主要是来自PubMed数据库的近期英文研究文章、相关综述文章以及病例系列/报告，时间从2010年起。
研究选择
大多数数据来自回顾性研究和病例系列。如果关于机制的较旧研究具有特别重要的意义，则予以纳入。
结果
通过对本综述的理解，读者应能够识别接受免疫CPI治疗患者中的特定皮肤疾病，对不良事件进行分级，并能够根据需要治疗或转诊患者。
结论
过敏症专科医生/免疫学家需要熟悉这些免疫相关的皮肤不良事件，因为随着CPI使用的不断扩大，其发生率将会增加，特别是因为肯定会有怀疑药物过敏的患者继续前来转诊。
Zotero 插件